0000950170-23-071467.txt : 20231219 0000950170-23-071467.hdr.sgml : 20231219 20231219160512 ACCESSION NUMBER: 0000950170-23-071467 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20231216 FILED AS OF DATE: 20231219 DATE AS OF CHANGE: 20231219 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Farquharson Andrew CENTRAL INDEX KEY: 0001865699 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-40672 FILM NUMBER: 231497278 MAIL ADDRESS: STREET 1: C/O RANI THERAPEUTICS HOLDINGS, INC. STREET 2: 2051 RINGWOOD AVENUE CITY: SAN JOSE STATE: CA ZIP: 95131 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Rani Therapeutics Holdings, Inc. CENTRAL INDEX KEY: 0001856725 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 2051 RINGWOOD AVENUE CITY: SAN JOSE STATE: CA ZIP: 95131 BUSINESS PHONE: (408) 457-3700 MAIL ADDRESS: STREET 1: 2051 RINGWOOD AVENUE CITY: SAN JOSE STATE: CA ZIP: 95131 4 1 ownership.xml 4 X0508 4 2023-12-16 0001856725 Rani Therapeutics Holdings, Inc. RANI 0001865699 Farquharson Andrew 2051 RINGWOOD AVE SAN JOSE CA 95131 true false false false false Stock Option (Right to Buy) 4.11 2023-12-16 4 D false 101276 D 2033-05-24 Class A Common Stock 101276 0 D Stock Option (Right to Buy) 2.84 2023-12-16 4 A false 101276 A 2033-05-24 Class A Common Stock 101276 101276 D The shares subject to the option vest in full on May 25, 2024, subject to the recipient's Continuous Service (as defined in the Issuer's 2021 Equity Incentive Plan) through such vesting date; provided that, if earlier, the shares subject to the option will vest in full upon the occurrence of either of the following events: the Issuer's next annual stockholder meeting or a Change in Control (as defined in the 2021 Equity Incentive Plan). The transactions reported herein reflect a one-time stock option repricing (the "Option Repricing") effective on December 16, 2023 (the "Repricing Date"). Pursuant to the Option Repricing, the exercise price of the repriced options has been amended to reduce the exercise price to $2.84 per share, the closing price of the Issuer's Common Stock on the Repricing Date. There is no change to the expiration dates or the vesting schedule of the repriced options. Svai Sanford. Attorney-in-Fact for Andrew Farquharson 2023-12-19